+

PE20030303A1 - FORMULACIONES DE INTERFERON ß HUMANO - Google Patents

FORMULACIONES DE INTERFERON ß HUMANO

Info

Publication number
PE20030303A1
PE20030303A1 PE2002000613A PE2002000613A PE20030303A1 PE 20030303 A1 PE20030303 A1 PE 20030303A1 PE 2002000613 A PE2002000613 A PE 2002000613A PE 2002000613 A PE2002000613 A PE 2002000613A PE 20030303 A1 PE20030303 A1 PE 20030303A1
Authority
PE
Peru
Prior art keywords
ifnß
interferon
formulations
human
solubilizers
Prior art date
Application number
PE2002000613A
Other languages
English (en)
Inventor
Michael Mccaman
Susanne Ottoboni
Erno Pungor
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20030303A1 publication Critical patent/PE20030303A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONSISTE ESENCIALMENTE DE: i)0,25mg/ml A 25mg/ml DE INTERFERON ß IFNß-1b BIOLOGICAMENTE ACTIVO NO GLICOSILADO QUE SE PRODUCE EN UN HUESPED BACTERIANO; ii)AMORTIGUADOR QUE CONTIENE DE 1mM A 100mM DE GLICINA, HCl; iii)AGUA, ESTERIL; CARACTERIZADA POR pH DE 2 A 4, ESTAR LIBRE DE ESTABILIZADORES CONVENCIONALES COMO ALBUMINA DE SUERO, NO CONTENER UNA CANTIDAD DETECTABLE DE SOLUBILIZADORES TAL COMO DETERGENTE. EL IFNß PUEDE SER UTIL PARA EL TRATAMIENTO DE ESCLEROSIS MULTIPLE
PE2002000613A 2001-07-09 2002-07-09 FORMULACIONES DE INTERFERON ß HUMANO PE20030303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30339501P 2001-07-09 2001-07-09

Publications (1)

Publication Number Publication Date
PE20030303A1 true PE20030303A1 (es) 2003-06-21

Family

ID=23171889

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000613A PE20030303A1 (es) 2001-07-09 2002-07-09 FORMULACIONES DE INTERFERON ß HUMANO

Country Status (7)

Country Link
US (2) US20030118548A1 (es)
JP (1) JP2004538275A (es)
AR (1) AR034749A1 (es)
PE (1) PE20030303A1 (es)
TW (1) TWI241193B (es)
UY (1) UY27373A1 (es)
WO (1) WO2003006053A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US20050008616A1 (en) * 2003-07-11 2005-01-13 Schering Aktiengesellschaft Recombinant human interferon-beta-1b polypeptides
WO2006033453A1 (ja) * 2004-09-22 2006-03-30 Juntendo Educational Foundation インターフェロン作用物質の活性増強剤
CN101056890B (zh) * 2004-11-10 2012-05-09 诺华疫苗和诊断公司 脱酰胺基干扰素-β
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
DOP2006000116A (es) * 2005-05-19 2007-01-31 Schering Ag Sistema mejorado de expresión regulada y sus usos.
EP1891224A1 (en) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
MX2008001396A (es) * 2005-07-29 2008-04-16 Novartis Ag Metodo y sistema para plegado in vitro de proteinas.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
DE2943016C2 (de) * 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) * 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
NL7907791A (nl) * 1979-10-23 1981-04-27 Stichting Rega V Z W Werkwijze voor het zuiveren van interferon.
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4643566A (en) * 1984-07-20 1987-02-17 Canon Kabushiki Kaisha Particle analyzing apparatus
DE3628468A1 (de) * 1986-08-21 1988-03-03 Thomae Gmbh Dr K Neue applikationsformen fuer (alpha)-interferone
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2687843A1 (fr) * 1992-02-24 1993-08-27 Motorola Semiconducteurs Transistor bipolaire lateral pnp et procede de fabrication.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP3466765B2 (ja) * 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
EE04266B1 (et) * 1996-12-24 2004-04-15 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
WO2003006053A1 (en) 2003-01-23
US20050163752A1 (en) 2005-07-28
TWI241193B (en) 2005-10-11
US20030118548A1 (en) 2003-06-26
UY27373A1 (es) 2003-02-28
JP2004538275A (ja) 2004-12-24
AR034749A1 (es) 2004-03-17

Similar Documents

Publication Publication Date Title
PE20020127A1 (es) Interleuquina 2 estabilizada
ES2602956T3 (es) Composiciones de antibiótico para tratamiento de conjuntivitis
PE38897A1 (es) Solucion acuosa de interferon alfa
CA2201749A1 (en) Stable aqueous alfa interferon solution formulations
CO5251404A1 (es) Compuestos antibioticos de azalida
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
PE20030303A1 (es) FORMULACIONES DE INTERFERON ß HUMANO
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
PE20000560A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
UY26704A1 (es) Nueva composición farmacéutica
SE0001899D0 (sv) New compounds
RU2008111632A (ru) ВОДНЫЕ КОМПОЗИЦИИ чФСГ
DE69231298D1 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
AU2001283353A1 (en) Compositions containing hypoglycemically active stilbenoids
IL174410A0 (en) Large scale preparation of alpha-1 proteinase inhibitor and use thereof
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
PE61699A1 (es) Composicion farmaceutica de lamivudina
BR9808722A (pt) Composições farmacêuticas de tizoxanida e nitazoxanida
ES2157221T3 (es) Composiciones metaloporfirinicas.
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
FR2821080B1 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载